Pages that link to "Q43577973"
Jump to navigation
Jump to search
The following pages link to A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells (Q43577973):
Displaying 50 items.
- Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation (Q24297095) (← links)
- Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function (Q24304442) (← links)
- Review: The HSP90 molecular chaperone-an enigmatic ATPase (Q26753822) (← links)
- Targeting Cell Survival Proteins for Cancer Cell Death (Q26765447) (← links)
- HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms (Q26778548) (← links)
- Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90 (Q26997981) (← links)
- Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers (Q27022514) (← links)
- Different Poses for Ligand and Chaperone in Inhibitor-Bound Hsp90 and GRP94: Implications for Paralog-Specific Drug Design (Q27654646) (← links)
- Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors (Q27673253) (← links)
- Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 (Q27679845) (← links)
- Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics (Q28254233) (← links)
- Targeting heat shock proteins in cancer (Q28298397) (← links)
- Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90 (Q28474428) (← links)
- Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes (Q28572341) (← links)
- The ATPases: a new family for a family-based drug design approach (Q30799661) (← links)
- Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase (Q31108274) (← links)
- Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. (Q31151322) (← links)
- Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions (Q33193145) (← links)
- Hsp90 inhibition decreases mitochondrial protein turnover (Q33303676) (← links)
- Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor (Q33330693) (← links)
- An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction (Q33408481) (← links)
- Cancer and virus leads by HTS, chemical design and SEA data mining (Q33508912) (← links)
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas (Q33588432) (← links)
- Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer (Q33710107) (← links)
- Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications (Q33899708) (← links)
- Probing the probes: fitness factors for small molecule tools (Q34001269) (← links)
- Protein chaperones: a composition of matter review (2008 - 2013). (Q34013266) (← links)
- Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects (Q34096497) (← links)
- Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs (Q34124337) (← links)
- Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide (Q34129993) (← links)
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans (Q34162151) (← links)
- Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions (Q34164027) (← links)
- HSP90 as a new therapeutic target for cancer therapy: the story unfolds (Q34482045) (← links)
- Hsp90 inhibitors as novel cancer chemotherapeutic agents (Q34583912) (← links)
- Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies (Q34657935) (← links)
- ATPases as drug targets: learning from their structure (Q34810356) (← links)
- Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. (Q35173052) (← links)
- Hsp90 molecular chaperone inhibitors: are we there yet? (Q35655105) (← links)
- Targeting multiple signal transduction pathways through inhibition of Hsp90. (Q35787276) (← links)
- Therapeutic and diagnostic implications of Hsp90 activation (Q35791991) (← links)
- Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment (Q35800838) (← links)
- Hsp90: the vulnerable chaperone (Q35913771) (← links)
- The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis (Q36059002) (← links)
- EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy (Q36103054) (← links)
- First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90 (Q36310262) (← links)
- Purine-scaffold Hsp90 inhibitors. (Q36426208) (← links)
- The role of hypoxia inducible factor-1 in cell metabolism--a possible target in cancer therapy (Q36539483) (← links)
- Hsp90 as a target for drug development (Q36635195) (← links)
- New approaches to molecular cancer therapeutics (Q36654909) (← links)
- Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease (Q36655158) (← links)